These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16472561)

  • 1. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
    Anderson FD; Gibbons W; Portman D
    Contraception; 2006 Mar; 73(3):229-34. PubMed ID: 16472561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
    Archer DF; Jensen JT; Johnson JV; Borisute H; Grubb GS; Constantine GD
    Contraception; 2006 Dec; 74(6):439-45. PubMed ID: 17157099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
    Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
    Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized study of an extended cycle oral contraceptive.
    Anderson FD; Hait H
    Contraception; 2003 Aug; 68(2):89-96. PubMed ID: 12954519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
    Kaunitz AM; Portman DJ; Hait H; Reape KZ
    Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
    Barbosa IC; Filho CI; Faggion D; Baracat EC
    Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
    Nakajima ST; Archer DF; Ellman H
    Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.
    Anderson FD; Gibbons W; Portman D
    Am J Obstet Gynecol; 2006 Jul; 195(1):92-6. PubMed ID: 16813747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
    Poindexter A; Reape KZ; Hait H
    Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.
    Anderson FD; Feldman R; Reape KZ
    Contraception; 2008 Feb; 77(2):91-6. PubMed ID: 18226671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen.
    Anderson FD; Hait H; Hsiu J; Thompson-Graves AL; Wilborn WH; Williams RF
    Contraception; 2005 Jan; 71(1):55-9. PubMed ID: 15639074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol.
    Kroll R; Reape KZ; Margolis M
    Contraception; 2010 Jan; 81(1):41-8. PubMed ID: 20004272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A look at the long-term safety of an extended-regimen OC.
    Davis MG; Reape KZ; Hait H
    J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
    Sulak PJ; Kuehl TJ; Coffee A; Willis S
    Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended- and continuous-cycle oral contraceptives.
    Shrader SP; Dickerson LM
    Pharmacotherapy; 2008 Aug; 28(8):1033-40. PubMed ID: 18657019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.